Credit Suisse | NBIX Message Board Posts

Neurocrine Biosciences, Inc.

  NBIX website

  •  Registered Members of Investor Village:
    Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password. 

     MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.  

    For assistance call 888-222-7309 or email

NBIX   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  46666 of 47286  at  11/12/2019 4:40:44 PM  by


Credit Suisse

Pretty much the same and, since KG is presenting next week in London, if there are any surprises I suspect he will be the one to announce them.
1.  Huntington's Chorea PIII trial results Q1 2021.
2.  Ingrezza continuing education mantra.  Seasonality effect in Q1 will likely be greater as more and more scrips are refills.  Took about a month and a half to work through in 2019.
3.  Opicapone will not be a specialty drug and probably be less than $600 per month.  After paying royalties and COGS, gross margin will be 62.5%.  Will owe $20 million upon approval to Bial.
4.  Acknowledged that both Neurocrine and Abbvie think acceptance for Orilissa has been slower than expected and Abbvie is working on new initiatives to boost sales.  Approval for UF expected Q2 2020 and there is hope UF will be more successful.  UF's patient profile is generally older and may be more motivated to seek treatment.
5.  CAH and VY-AADC same.

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 201
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
46667 Re: Credit Suisse grega22 0 11/12/2019 6:17:20 PM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by